Myonex Finalizes Creapharm Deal
The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.
Myonex, a clinical trial supply company,has now finalized the purchase of Creapharm’s pharmaceutical services business.1 The deal is expected to be beneficial for both pharma and biotech companies in the clinical and commercial stages; this also includes companies in the advanced therapies sector.
Moving forward, Creapharm’s clinical packaging and distribution services, commercial packaging operations, and bioservices will go by the name “Creapharm, a Myonex company.”
"We are thrilled to have completed the acquisition of Creapharm, a milestone that expands our services and enhances our capabilities for clients and the industry. Together, we are poised to meet the dynamic needs of our clients with agility, flexibility, and reliability," noted James Lovett, CEO of Myonex.
Myonex will also be adding a new executive to their board.
"We are excited to welcome Eric Placet, the visionary founder and former CEO of Creapharm, to the Myonex board of directors. His decision to reinvest in the company is a testament to our shared commitment to excellence and innovation,” said Mike Cohen, Myonex’s executive chairman. “Additionally, we are pleased to announce the appointment of Carla Da Costa as our chief operating officer, further strengthening our executive team as we continue to drive growth and deliver exceptional value to our clients."
Back in April, in an effort to support clinical trial sponsor’s trial designs with direct-to-patient and home healthcare provider capabilities, Myonex also acquired SaveWay Compounding Pharmacy.2 The deal helped increase patients’ with their access to trial medication and necessary equipment.
“With this acquisition, Myonex will support SaveWay’s expansion into clinical trials and accelerate the growth of direct-to-patient services. SaveWay has a unique opportunity to grow and expand serving patients across the US in clinical trials by dispensing investigational medicinal product, commercial medications, and specialized compounded medications directly to clinical trial patients,” commented Pradeep Chilakapati, RPh, managing partner and pharmacist at SaveWay. “We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today’s trends in clinical trials.”
References
1. Myonex Closes Creapharm Acquisition, Expanding Global Services. Myonex. May 2, 2024. Accessed May 7, 2024. https://www.myonex.com/about-myonex/news/myonex-closes-creapharm-acquisition-expanding-global-services/
2. Myonex Announces Acquisition of Saveway Compounding Pharmacy to Expand Its Clinical Trial Services Across the US. Myonex. April 9, 2024. Accessed May 7, 2024. https://www.myonex.com/about-myonex/news/myonex-announces-acquisition-of-saveway-compounding-pharmacy/
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
